As a result of this research, a nanoparticulate formulation has been created that specifically targets the acidic tumor interstium and cathepsin B. Cathepsin B is a proteolytic enzyme common in malignant tumor microenvironments, and cancer cells modulate its production and release extensively based on interstitial pH. Here, CTSB is linked to cancer.